a2 Milk's 45% Fall Was Bigger Than the Numbers Behind It

A supply chain crunch and a minor US recall triggered an outsized sell-off, before Chinese approval and a special dividend began rebuilding confidence.

24 Aug 2026 · 4 min read

a2 Milk fell more than 45 percent from around $9.80 to a low of $5.32 through April and May 2026, hit first by a supply-chain-driven earnings downgrade and then a US infant formula recall, before Chinese regulatory approval and a $300 million special dividend sparked a recovery that has since been tempered by a more cautious FY27 outlook.

A supply chain crunch cuts guidance

Pendal Group said FY26 earnings were downgraded around 11 percent in April as increased cereulide testing at both manufacturing facilities and on entry into China added four weeks to the supply chain, and combined with low inventory tied to supplier Synlait's ongoing manufacturing challenges, left a2 Milk without enough product to sell through into China. Perpetual Asset Management said the stock fell nearly 26 percent that month after management cut EBITDA margin guidance to 14 to 14.5 percent from 15.5 to 16 percent, with net profit now expected flat or below the prior year. Antares Capital said the limited availability of the company's China Label Stage 1 product was particularly damaging given its importance in establishing long-term brand engagement, with the shortfall attributed to issues at key supplier Synlait, while Solaris Investment Management noted underlying demand remained strong even as production and regulatory delays drove higher costs, including air freight.

A US recall compounds the damage

May brought a second blow. Pendal Group described a voluntary recall of US-label a2 Platinum infant formula as, rationally, a minor issue, covering three batches, around 63,000 tins of which about 16,000 had been sold to consumers, of an already-discontinued product representing roughly 0.1 percent of revenue, with no confirmed infant illness reported. Perpetual Asset Management said the recall, triggered by retrospective cereulide contamination testing, caused a 9.9 percent single-day share price fall and a 24.15 percent decline for the month overall, even though the direct financial impact was modest at around 0.2 percent of FY26 infant formula sales, because markets were spooked by the risk of broader brand damage.

Rationally, the issue is minor: the recall relates to three batches of a product that had already been discontinued, impacting about 0.1% of revenue. No confirmed incidents of infant illness have been reported.

— Pendal Group, Newsletter, May 2026

Solaris Investment Management flagged broader concerns around reputational damage, regulatory scrutiny and flow-on effects to brand equity and US licensing arrangements, while Firetrail Investments said the recall, though covering an immaterial volume of a discontinued product in a non-core market, raised investor concern about the risk of further recalls on top of April's supply issues.

Regulatory approval and a special dividend spark a recovery

Pendal Group reported in June that a2 Milk declared a previously flagged $300 million special dividend after receiving Chinese regulatory approval for two China Label registrations tied to its Pokeno manufacturing acquisition, fully franked and equating to a roughly 4.8 percent yield. Antares Capital said the regulatory approval removed a key uncertainty around access to China, the company's largest market, and Firetrail Investments said the stock rebounded as investors gained comfort the supply issues were short-lived. Cadence Capital initiated a new position, describing a2 Milk as a former market darling that had not met its fundamental criteria at its prior extreme valuation, but now viewed the share price trend as beginning to reverse. Paradice Investment Management said the stock fell 22 percent on near-term China infant formula channel dynamics but retained conviction in the brand's strength and market share trajectory, increasing its position on the view the weakness reflected channel timing rather than any deterioration in market share.

A2 Milk's recent weakness reflects near-term channel dynamics rather than deterioration in its market share trajectory.

— Paradice Investment Management, Quarterly Report, June 2026

July's update reassures, but August's guidance disappoints again

Pendal Group described a reassuring July update confirming the China Label supply-chain issues had largely been resolved, with FY26 net profit now expected slightly higher than FY25, an improvement on April's flat-to-down guidance, shifting attention toward FY27 and how quickly customers lost during the disruption return to the brand. That optimism was tempered in August, when FY26 results came in line but FY27 guidance was about 6 percent light at the bottom line, as earnings get pushed out six to twelve months following the fourth-quarter supply disruption, driving roughly 10 percent downgrades to outer-year estimates. Pendal noted management is taking a deliberately conservative approach to restocking after two and a half months of stock-outs, while still seeing good momentum ahead from the company's own supply chain self-help measures.

What fund managers say they are watching next is how quickly customers lost during the China Label disruption return to the brand, whether the deliberately conservative restocking plan avoids further shortages, whether any additional product-quality concerns emerge, and whether the newly approved manufacturing facility delivers the supply reliability needed to rebuild trust after two damaging incidents in consecutive months.